^
    Apply
    Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer (REMAIN) (NCT06029270)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    07/15/2024
    Primary completion :
    04/30/2029
    Completion :
    04/30/2029
    PD-L1 • LAG3
    |
    Opdivo (nivolumab) • cisplatin • carboplatin • gemcitabine • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar)
    Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma (CA224-094) (NCT04552223)
    Phase 2
    Jose Lutzky, MD
    Active, not recruiting
    Last update posted :
    02/13/2025
    Initiation :
    11/10/2020
    Primary completion :
    01/04/2024
    Completion :
    01/04/2026
    LAG3 • CTLA4
    |
    Opdivo (nivolumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)
    Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab (GIANT) (NCT06816927)
    Phase 2
    Duke University
    Not yet recruiting
    Last update posted :
    02/10/2025
    Initiation :
    06/01/2025
    Primary completion :
    06/01/2029
    Completion :
    06/01/2031
    MGMT
    |
    Opdivo (nivolumab) • relatlimab (BMS-986016)
    Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCI-MATCH) (NCT02465060)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    08/17/2015
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    MSI • CD4
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bicalutamide • leucovorin calcium • bendamustine • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • GSK2636771 • Zirabev (bevacizumab-bvzr) • defactinib (VS-6063) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Provenge (sipuleucel-T) • TQB2440 (pertuzumab biosimilar) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • BCD-178 (pertuzumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)
    ARID1A and/or KDM6A Mutation and CXCL13 Expression (NCT04953104)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    01/29/2025
    Initiation :
    09/21/2021
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    ARID1A • CXCL13
    |
    ARID1A mutation
    |
    Opdivo (nivolumab) • relatlimab (BMS-986016)
    Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer (NCT03642067)
    Phase 2
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Completed
    Last update posted :
    01/28/2025
    Initiation :
    02/12/2019
    Primary completion :
    02/23/2024
    Completion :
    09/18/2024
    PD-L1
    |
    Opdivo (nivolumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)
    A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) (RELATIVITY-104) (NCT04623775)
    Phase 2
    Bristol-Myers Squibb
    Active, not recruiting
    Last update posted :
    12/20/2024
    Initiation :
    02/17/2021
    Primary completion :
    01/11/2024
    Completion :
    01/30/2026
    PD-L1
    |
    Opdivo (nivolumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • relatlimab (BMS-986016)
    Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma (NCT06295159)
    Phase 2
    H. Lee Moffitt Cancer Center and Research Insti...
    Recruiting
    Last update posted :
    12/17/2024
    Initiation :
    05/17/2024
    Primary completion :
    07/01/2027
    Completion :
    07/01/2027
    PD-L1
    |
    Yervoy (ipilimumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)
    Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer (CA224-056) (NCT04080804)
    Phase 2
    Dan Zandberg
    Recruiting
    Last update posted :
    12/13/2024
    Initiation :
    12/20/2019
    Primary completion :
    05/31/2026
    Completion :
    09/30/2026
    TMB • LAG3
    |
    CD8 positive
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016)
    Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases (CA209-6D9) (NCT05704933)
    Phase 1
    H. Lee Moffitt Cancer Center and Research Insti...
    Active, not recruiting
    Last update posted :
    12/09/2024
    Initiation :
    06/06/2023
    Primary completion :
    06/07/2024
    Completion :
    06/01/2025
    CD8 • PD-1 • IFNG • CD4 • IL2 • IL10
    |
    PD-1 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)
    Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor (NCT03607890)
    Phase 2
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Recruiting
    Last update posted :
    10/23/2024
    Initiation :
    11/16/2018
    Primary completion :
    10/01/2025
    Completion :
    10/01/2025
    MSI
    |
    MSI-H/dMMR
    |
    Opdivo (nivolumab) • relatlimab (BMS-986016)
    Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting (NCT03743766)
    Phase 2
    John Kirkwood
    Completed
    Last update posted :
    09/25/2024
    Initiation :
    03/29/2019
    Primary completion :
    07/03/2024
    Completion :
    07/03/2024
    PD-1 • LAG3
    |
    PD-1 expression • LAG3 expression
    |
    Opdivo (nivolumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)
    iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer (NCT03867799)
    Phase 2
    Royal Marsden NHS Foundation Trust
    Active, not recruiting
    Last update posted :
    06/14/2024
    Initiation :
    03/27/2019
    Primary completion :
    10/21/2022
    Completion :
    09/01/2024
    EGFR
    |
    Opdivo (nivolumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)
    IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) (NCT06112314)
    Phase 3
    Immunocore Ltd
    Recruiting
    Last update posted :
    06/13/2024
    Initiation :
    12/18/2023
    Primary completion :
    12/01/2026
    Completion :
    12/01/2027
    BRAF • HLA-A
    |
    BRAF mutation • BRAF V600 • HLA-A*02
    |
    Opdualag (nivolumab/relatlimab-rmbw) • brenetafusp (IMC-F106C) • relatlimab (BMS-986016)
    Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors (NCT05629546)
    Phase 1
    Washington University School of Medicine
    Not yet recruiting
    Last update posted :
    06/11/2024
    Initiation :
    06/30/2024
    Primary completion :
    09/30/2028
    Completion :
    06/30/2030
    PD-L1
    |
    Opdivo (nivolumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)
    A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread (CheckMate142) (NCT02060188)
    Phase 2
    Bristol-Myers Squibb
    Active, not recruiting
    Last update posted :
    05/10/2024
    Initiation :
    03/12/2014
    Primary completion :
    06/28/2024
    Completion :
    06/28/2024
    MSI
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Cotellic (cobimetinib) • Darzalex (daratumumab) • relatlimab (BMS-986016)
    Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin (CA209-587) (NCT04204837)
    Phase 2
    Salzburger Landeskliniken
    Recruiting
    Last update posted :
    04/18/2024
    Initiation :
    03/06/2017
    Primary completion :
    12/01/2026
    Completion :
    12/01/2027
    PD-L1 • LAG3
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • relatlimab (BMS-986016)
    Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies (NCT04541108)
    Phase 1
    Presage Biosciences
    Recruiting
    Last update posted :
    04/18/2024
    Initiation :
    07/26/2021
    Primary completion :
    12/01/2031
    Completion :
    12/01/2031
    CD8 • TNFA • CD163 • CD4 • NCAM1 • CASP3 • CD68 • GZMB • CD86
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • carboplatin • paclitaxel • 5-fluorouracil • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • BMS-986299 • MK-0482 • MK-4830 • dazostinag (TAK-676) • sabestomig (AZD7789)
    Neoadjuvant and Adjuvant Checkpoint Blockade (NCT02519322)
    Phase 2
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    04/05/2024
    Initiation :
    02/02/2016
    Primary completion :
    01/26/2023
    Completion :
    01/26/2023
    PD-L1
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016)
    A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM) (NCT03310619)
    Phase 1/2
    Celgene
    Completed
    Last update posted :
    04/04/2024
    Initiation :
    12/20/2017
    Primary completion :
    02/15/2023
    Completion :
    02/15/2023
    BCL2 • BCL6
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    Opdivo (nivolumab) • Imfinzi (durvalumab) • Imbruvica (ibrutinib) • Breyanzi (lisocabtagene maraleucel) • avadomide (CC-122) • iberdomide (CC-220) • relatlimab (BMS-986016) • golcadomide (CC-99282)
    Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma (Neo-MCC) (NCT06151236)
    Phase 2
    Melanoma Institute Australia
    Recruiting
    Last update posted :
    03/15/2024
    Initiation :
    03/11/2024
    Primary completion :
    04/01/2026
    Completion :
    04/01/2034
    TMB
    |
    PD-L1 expression
    |
    Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)
    Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG (IMAGINE) (NCT04062656)
    Phase 2
    University Hospital, Essen
    Active, not recruiting
    Last update posted :
    03/11/2024
    Initiation :
    09/26/2019
    Primary completion :
    03/01/2024
    Completion :
    06/01/2025
    LAG3
    |
    LAG3 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • docetaxel • 5-fluorouracil • oxaliplatin • leucovorin calcium • relatlimab (BMS-986016)
    Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy (NCT04326257)
    Phase 2
    Dan Zandberg
    Active, not recruiting
    Last update posted :
    02/07/2024
    Initiation :
    06/05/2020
    Primary completion :
    08/12/2023
    Completion :
    08/12/2024
    LAG3 • CTLA4
    |
    LAG3 expression • CTLA4 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)
    Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla (NCT05347212)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/06/2024
    Initiation :
    09/22/2022
    Primary completion :
    07/16/2027
    Completion :
    07/16/2027
    SMARCB1
    |
    SMARCB1 negative
    |
    Opdivo (nivolumab) • relatlimab (BMS-986016)
    Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18) (NCT02658981)
    Phase 1
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Completed
    Last update posted :
    10/06/2023
    Initiation :
    08/24/2016
    Primary completion :
    04/30/2022
    Completion :
    10/03/2023
    MGMT
    |
    Opdivo (nivolumab) • relatlimab (BMS-986016) • urelumab (BMS-663513)
    Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade (NCT03493932)
    Phase 1
    National Institute of Neurological Disorders an...
    Completed
    Last update posted :
    09/21/2023
    Initiation :
    09/24/2018
    Primary completion :
    04/21/2023
    Completion :
    06/27/2023
    IFNG
    |
    IFNG elevation
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016)
    Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma (NCT04697576)
    Phase 1
    Carlo Contreras
    Recruiting
    Last update posted :
    07/18/2023
    Initiation :
    10/20/2021
    Primary completion :
    12/31/2023
    Completion :
    12/31/2025
    CD20 • PD-1 • NCAM1 • GZMB • FOXP3
    |
    TILs
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)
    A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma (NCT05077280)
    Phase 2
    California Pacific Medical Center Research Inst...
    Recruiting
    Last update posted :
    12/06/2022
    Initiation :
    09/20/2021
    Primary completion :
    03/01/2024
    Completion :
    03/01/2026
    PD-1
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)
    Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer (NESCIO) (NCT05148546)
    Phase 2
    The Netherlands Cancer Institute
    Recruiting
    Last update posted :
    05/09/2022
    Initiation :
    04/28/2022
    Primary completion :
    04/01/2024
    Completion :
    04/01/2029
    PD-L1 • PD-1 • LAG3
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016)